Update shared on24 Jul 2025
Fair value Increased 6.13%With Glenmark Pharmaceuticals' future P/E ratio edging up from 31.26x to 32.17x while net profit margin remains stable, the consensus analyst price target is unchanged at ₹2061.
What's in the News
- Glenmark launched TEVIMBRA® (tislelizumab), an anti-PD-1 monoclonal antibody for NSCLC and ESCC, marking its entry into immune-oncology in India.
- Signed a Letter of Intent with AcuCort AB to distribute and market Zeqmelit® in six European countries, with plans to finalize a binding agreement in 2025.
- Announced the launch of BRUKINSA (zanubrutinib), a BTK inhibitor, in India for five B-cell malignancies, filling a major therapeutic gap with superior efficacy and safety.
- Issued 2026 revenue growth guidance of 10% to 12%.
- Held board meetings to consider granting stock options and to approve audited financial results and potential dividend for FY25.
Valuation Changes
Summary of Valuation Changes for Glenmark Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, at ₹2061.
- The Future P/E for Glenmark Pharmaceuticals has risen slightly from 31.26x to 32.17x.
- The Net Profit Margin for Glenmark Pharmaceuticals remained effectively unchanged, at 15.79%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.